• Mathias Schmidt, Ph.D.

    President and Chief Executive Officer

    Dr. Schmidt joined ArmaGen as the president and chief executive officer, as well as member of ArmaGen’s board of directors, in October 2016. Dr. Schmidt has more than 17 years of global biopharmaceutical industry experience in executive management focused on the research and development of biotherapeutics and pharmaceuticals. Prior to ArmaGen, he held various positions with Takeda Pharmaceuticals and its subsidiaries since 2001, including oncology drug discovery, early alliance management and overseeing biologics. He joined Takeda California in 2012 as Vice President of Biological Sciences where he built a highly functional Biotherapeutics unit serving all therapeutic indications and all research sites within the global Takeda organization. In 2011, he was awarded the venia legendi in pharmacology from the University of Konstanz. He and his team developed a HER-2 specific immunotoxin that subsequently entered the clinic when he studied at the University of Freiburg. After working for several years at various cancer hospitals in Germany and the U.S., he joined the pharmaceutical industry in 1999, where he developed a great passion for drug discovery and development, especially for protein therapeutics.

    He holds an M.S. degree in Biotechnology from the University of Stuttgart (Germany) and a Ph.D. in Tumor Biology (summa cum laude) from the University of Freiburg. He studied cellular biology and pharmacology at the University of Constance.

  • William M. Pardridge, M.D.

    Founder and Chief Scientific Officer

    Dr. Pardridge formed ArmaGen in 2003 and supported the company the first 10 years with $20 million in non-dilutive funding. Dr. Pardridge, who is a Distinguished Professor Emeritus, UCLA, is a recognized leader in blood brain barrier (BBB) research. He has focused on the area since 1970, and is credited with inventing antibody directed receptor-mediated transcytosis technology, the liposome technology for non-viral, non-invasive gene therapy of the brain, and the field of BBB genomics. He is the author of over 500 publications, more than 450 of which focus on the BBB. Dr. Pardridge is board certified in Internal Medicine, and Endocrinology and Metabolism.

  • Martin Heidecker, Ph.D.

    Boehringer Ingelheim Venture Fund (BIVF)

    Dr. Heidecker has 15 years of investment and commercial experience with venture capital and global pharmaceutical companies. He established the U.S.-office of Boehringer Ingelheim Venture Fund (BIVF) where he is focusing on biotech seed-investments. He previously held Senior Business Analyst and Director roles within the Global Business Analysis department, providing strategic marketing support for CNS, Women’s Health and Oncology. Prior to joining Boehringer Ingelheim (BI), Martin held several positions within the global Business Intelligence Department of Solvay Pharmaceuticals, focusing primarily on compounds in early clinical stages. Before Solvay, Martin was an investment manager at Bayern Kapital. During this time, he led co-investments in early stage drug development, medical devices, and bioinformatic companies. Dr. Heidecker holds a Ph.D. in Biology, focusing on membrane transport proteins in his thesis. He also has a Master’s degree in Biology and Economics.

  • Jayson Punwani, Ph.D.

    Partner, Takeda Ventures, Inc.

    Dr. Jayson Punwani joined TVI in October 2017 as Investment Director and is based in San Diego, CA. Prior to TVI, Dr. Punwani was a Senior Principal at Pappas Ventures, where he represented the firm as an observer on the Board of Directors for Balance Therapeutics, CardioDx, CoLucid (acquired by Eli Lilly), Lumena Pharmaceuticals (acquired by Shire), and OrphoMed, among others. Prior to his six years on the investment team at Pappas Ventures, he was co-manager for the Kenan-Flagler Private Equity Fund. He also worked in the Office of Technology Development at UNC-Chapel Hill, where he developed and executed commercialization and licensing strategies for biomedical technologies. Dr. Punwani earned his M.B.A. from the University of North Carolina at Chapel Hill, his Ph.D. in biology from the University of Utah, and his B.S. in Biology with a minor in chemistry from the College of New Jersey.

  • Masaji Matsuoka (Observer)

    Senior Associate, Mitsui Global Investment

    Mr. Matsuoka is a Director in the Investment Division of Mitsui Global Investment. He previously worked in the Principal Investment Division at Mitsui & Co. Ltd, where he was involved with various investment transactions within the healthcare and industrial sectors. Prior to that, he was in the Asset Management Division at Mitsui & Co., focusing on the alternative fund business and fund raising. He started his career at Mitsui in 2004. He holds a Bachelor of Law from the University of Tokyo.